Dimensional Fund Advisors LP Eiger Bio Pharmaceuticals, Inc. Transaction History

Dimensional Fund Advisors LP

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 12, 2023	SELL	$0.89 - $2.52 $179,484 - $508,203	-201,668 Reduced 33.25%	404,820 $364,000
Q4 2022 Feb 09, 2023	SELL	$1.02 - $7.48 $56,998 - $417,989	-55,881 Reduced 8.44%	606,488 $715,000
Q3 2022 Nov 10, 2022	BUY	$6.04 - $9.66 $753,514 - $1.21 Million	124,754 Added 23.21%	662,369 $4.99 Million
Q2 2022 Aug 12, 2022	BUY	$4.99 - $8.96 $747,621 - $1.34 Million	149,824 Added 38.64%	537,615 $3.39 Million
Q1 2022 May 13, 2022	BUY	$3.84 - $9.74 $392,267 - $994,970	102,153 Added 35.76%	387,791 $3.22 Million
Q4 2021 Feb 09, 2022	BUY	$5.12 - $8.19 $382,489 - $611,833	74,705 Added 35.42%	285,638 $1.48 Million
Q3 2021 Nov 12, 2021	BUY	$6.68 - $9.1 $155,403 - $211,702	23,264 Added 12.4%	210,933 $1.41 Million
Q2 2021 Aug 12, 2021	BUY	$7.82 - $9.23 $179,304 - $211,634	22,929 Added 13.92%	187,669 $1.6 Million
Q1 2021 May 14, 2021	BUY	$8.44 - $12.66 $477,113 - $715,669	56,530 Added 52.24%	164,740 $1.46 Million
Q4 2020 Feb 25, 2021	BUY	$7.98 - $12.29 $863,515 - $1.33 Million	108,210 New	108,210 $1.33 Million

748K

Ticker EIGR
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 43,966,800
Market Cap $418M
Description
Eiger BioPharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of targeted therapies for rare and ultra-rare diseases in the United States and internationally. Its lead product candidate is Lonafarnib, an orally bioavailable, small molecule, which is in Phase III clinical trials to ...

Get notified when there are updates to the investment portfolio of Dimensional Fund Advisors LP, based on Form 13F filings with the SEC.

Stay updated on Dimensional Fund Advisors LP with notifications on news.